Clinical trials testing broadly neutralizing antibody against HIV demonstrate efficacy against sensitive strains
The proof-of-concept AMP studies demonstrated that a broadly neutralizing antibody (bnAb) called VRC01 was effective at preventing the acquisition of HIV strains to the 30% of strains that were sensitive to the bnAb. This ...
Mar 17, 2021
0
25